Temple University

Thomas Jefferson University

Johns Hopkins University

Nova Southeastern University

Universita Di Napoli Federico Ii

Walter J Koch

Kamel Khalili

Weizhong Zhu

Arthur M Feldman

Douglas G Tilley

Nazareno Paolocci

Ning Feng

Joseph E Rabinowitz

Patrick Most

Alessandro Cannavo

Giuseppe Rengo

Sarah M Schumacher-Bass

Anastasios Lymperopoulos

Sven T Pleger

Compositions are directed to BCL2-associated athanogene 3 (BAG3) molecules and agents which modulate expression of BAG3 molecules. Pharmaceutical composition for administration to patients, for example, patients with heart failure, comprise one or more BAG3 molecules or agents which modulate expression of BAG3. Methods of treatment and identifying candidate therapeutic agents are also provided.

BAG3 as a target for therapy of heart failure

The present invention relates to compositions and methods for the treatment of heart failure.

Methods for treating heart failure with a TRKB agonist

This invention is generally related to novel compositions for treating or preventing heart failure. Specifically, the disclosure provides a composition comprising an amino-terminal domain of Beta.adrenergic receptor kinase-1 (Beta.ARKnt) peptide, or a nucleic acid encoding Beta.ARKnt. Further disclosed are methods of using the compositions for treating or preventing heart failure in a subject or for altering Beta.-adrenergic receptor (Beta.AR) density in a subject.

Methods for treating heart failure using beta-ARKnt peptide

The invention concerns the contribution of elevated levels of circulating alsosterone to heart disease and other hyperaldosteronic conditions. Since activation of &#x3b2;-arrestin 1(&#x3b2;arr1) by the Angiotensin II (AngII) type 1 receptor (ATR) mediates AngII-induced aldosterone production, &#x3b2;-arrestin 1(&#x3b2;arr1) is a therapeutic target for heart disease. The invention provides a &#x3b2;arr1 protein fragment comprising the C-terminus of &#x3b2;arr1 (&#x3b2;arr1ct; SEQ ID NO:3), compositions containing this protein fragment, and methods of using this protein fragment to reduce elevated levels of aldosterone in heart disease and other hyperaldosteronic conditions by inhibition of &#x3b2;-arrestin 1(&#x3b2;arr1). These compositions and methods are of therapeutic benefit in chronic heart failure and progression to heart failure after myocardial infarction (MI). Additionally, the invention provides an AngII peptide analog (SEQ ID NO:4), compositions containing this analog, and methods of using this analog for stimulation of &#x3b2;arr1 activity and aldosterone production.

Compositions comprising &#x3b2;-arrestin 1 and methods of use thereof for therapeutic modulation of aldosterone levels in heart disease

The invention provides nucleic acid segments, compositions and methods for the treatment of heart failure, vascular dysfunction, endothelial dysfunction, diabetes, [Ca]i regulation and NO synthase dysfunction. Adeno-associated and adenovirus are used as gene delivery vectors for the nucleic acid segments to product long term over-expression of S100A1, a small calcium sensing protein associated with the disclosed ailments and dysfunctions.

Tissue specific gene therapy treatment

Growing community of inventors

Broomall, PA, United States of America

Walter J Koch